

Crystallization and preliminary X-ray crystallographic analysis of PBPD2 from *Listeria monocytogenes*

Hyung Jin Cha,[‡] Jae-Hee Jeong[‡]
and Yeon-Gil Kim*

Pohang Accelerator Laboratory, Pohang
University of Science and Technology, Pohang
790-784, Republic of Korea

[‡] These authors contributed equally to this work.

Correspondence e-mail:
ygkim76@postech.ac.kr

Received 28 November 2013

Accepted 10 March 2014

Penicillin-binding proteins (PBPs), which mediate the peptidoglycan biosynthetic pathway in the bacterial cell wall, have been intensively investigated as a target for the design of antibiotics. In this study, PBPD2, a low-molecular-weight PBP encoded by *lmo2812* from *Listeria monocytogenes*, was overexpressed in *Escherichia coli*, purified and crystallized at 295 K using the sitting-drop vapour-diffusion method. The crystal belonged to the primitive orthorhombic space group $P2_12_12_1$, with unit-cell parameters $a = 37.7$, $b = 74.7$, $c = 75.1$ Å, and diffracted to 1.55 Å resolution. There was one molecule in the asymmetric unit. The preliminary structure was determined by the molecular-replacement method.

1. Introduction

The synthetic pathway of peptidoglycan, which is the major component of the bacterial cell wall, has been extensively investigated as a target for the design of antibacterial agents including β -lactam antibiotics. The peptidoglycan layer is responsible for protecting bacteria from osmotic pressure and maintaining cell morphology (Vollmer *et al.*, 2008; Popham & Young, 2003). The peptidoglycan layer is a mesh-like structure of alternating *N*-acetylglucosamine and *N*-acetylmuramic acid moieties that are cross-linked by peptapeptide chains (Lovering *et al.*, 2012). The assembly of peptidoglycan chains is carried out by penicillin-binding proteins (PBPs) through transglycosylation and transpeptidation reactions (Sauvage *et al.*, 2008). PBPs are classified into two groups: high-molecular-weight (HMW) and low-molecular-weight (LMW) PBPs (Sauvage *et al.*, 2008). The HMW PBPs are further divided into class A and class B PBPs. The class A PBPs are bifunctional enzymes which have transglycosylase and transpeptidase activities, whereas the class B PBPs exhibit only transpeptidase activity. The LMW PBPs generally act as DD -carboxypeptidase and are involved in the control of cell morphology and cell division (Ghosh *et al.*, 2008; Nelson & Young, 2001).

Listeria monocytogenes is a Gram-positive pathogenic bacterium that causes a serious food-borne infectious disease called listeriosis with a fatality rate of 25–30% (Southwick & Purich, 1996). For the treatment of listeriosis, ampicillin is used either alone or in combination with other medications (Hof *et al.*, 1997). Although the penicillin-related β -lactams are used as a gold standard for the treatment of listeriosis, the molecular basis of the action of the antibiotics is largely unknown.

In a previous study, five PBPs in *L. monocytogenes* were found using radiolabelled β -lactams: two HMW class A enzymes (PBP1 and PBP4), two HMW class B enzymes (PBP2 and PBP3) and one LMW enzyme (PBP5) (Vicente *et al.*, 1990). Recently, an additional four PBPs including PBPD2 were identified by both *in silico* analysis and binding assays using the fluorescent antibiotic BOCILLIN FL (Korsak *et al.*, 2010). *LmPBPD2* encoded by *lmo2812* from *L. monocytogenes* was found to be a LMW PBP exhibiting DD -carboxypeptidase activity (Korsak *et al.*, 2010). The overall fold of *LmPBPD2* may be most similar to the structure of the *Escherichia coli* LMW PBP6 (PDB entry 3it9; Chen *et al.*, 2009), which shows the highest sequence identity to *LmPBPD2* (32%) among solved PBP structures. However, the structural characteristics of LMW PBPs in *L. monocytogenes* have not been reported.




Table 1

Diffraction statistics.

Values in parentheses are for the highest resolution shell. A 0σ cutoff filter was applied during the scaling process.

X-ray source	Beamline BL-1A, PF
Wavelength (Å)	1.100
Resolution (Å)	37.68–1.55 (1.63–1.55)
Space group	$P2_12_12_1$
Unit-cell parameters (Å)	$a = 37.7, b = 74.7, c = 75.1$
Completeness (%)	96.9 (80.6)
R_{merge}^\dagger (%)	9.1 (39.4)
Multiplicity	5.3 (3.6)
Average $I/\sigma(I)$	10.8 (3.3)

$^\dagger R_{\text{merge}} = \frac{\sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle|}{\sum_{hkl} \sum_i I_i(hkl)}$, where $I_i(hkl)$ and $\langle I(hkl) \rangle$ are the observed intensity and the mean intensity of related reflections, respectively.

Here, we report the cloning, expression, purification, crystallization and preliminary X-ray crystallographic analysis of *LmPBPD2* (Lmo2812). The structural information on *LmPBPD2* will contribute to the design of better inhibitory agents against PBPs, therefore achieving more effective treatment for infections by bacteria, including *L. monocytogenes*.

2. Materials and methods

2.1. Cloning, expression and purification of PBPD2 (Lmo2812)

The gene encoding *LmPBPD2* (UniProt accession No. Q8Y3M3) was amplified by the polymerase chain reaction (PCR) with *Pfu* DNA polymerase from genomic DNA of *L. monocytogenes* EGD. The primers were 5'-CCGAAGGATCCTCTACGGAGCAACCAACTTATAC-3' (forward) and 5'-CCGAAGCTCGAGCTAATCTTCTTTAAACCAACCTCC-3' (reverse), containing *Bam*HI and *Xho*I restriction sites, respectively (bold). The PCR product was subcloned into the *Bam*HI- and *Xho*I-digested pProExHTb vector (Invitrogen, USA) to generate an expression plasmid encoding residues 21–272 of *LmPBPD2* with an N-terminal His₆ tag. The *lmo2812* gene insertion was confirmed by DNA sequencing. The resulting plasmid was transformed into the expression host *E. coli* B834(DE3) cells (Novagen, USA) harbouring the pRIL plasmid obtained from BL21(DE3)RIL cells (Stratagene, USA). The transformed cells were




Figure 1
SDS-PAGE of purified *LmPBPD2*. Lane *M*, molecular-weight markers (labelled in kDa); lane *A*, purified *LmPBPD2*.

then grown at 310 K in Luria–Bertani medium containing $100 \mu\text{g ml}^{-1}$ ampicillin and $34 \mu\text{g ml}^{-1}$ chloramphenicol until the OD_{600} reached 0.5–0.6. Expression of recombinant protein was induced with 0.5 mM isopropyl β -D-1-thiogalactopyranoside and the cells were incubated for 18 h at 295 K. The cells were harvested by centrifugation at 5000g at 277 K and were resuspended in ice-cold buffer *A* (30 mM Tris–HCl pH 8.0, 0.3 M NaCl). The resuspended cells were lysed by sonication and the lysate was centrifuged at 15 000g for 30 min.

The supernatant was loaded onto a 5 ml HisTrap FF column (GE Healthcare, Sweden) equilibrated with buffer *A*. After washing with buffer *A* supplemented with 20 mM imidazole, the bound protein was eluted with a solution consisting of 30 mM Tris–HCl pH 8.0, 50 mM NaCl, 200 mM imidazole. To remove the hexahistidine tag, the eluted fraction was digested overnight with TEV protease (Invitrogen, USA) at a ratio of 1:100(w:w) at 277 K. The target protein was then applied onto a 5 ml HiTrap Q column (GE Healthcare, Sweden) and eluted with a linear gradient of 50–1000 mM NaCl in a buffer consisting of 30 mM Tris–HCl pH 8.0. The eluted protein was further purified by size-exclusion chromatography on a Superdex 200 column (GE Healthcare, Sweden) equilibrated with 10 mM Tris–HCl pH 8.0, 100 mM NaCl. The fractions containing *LmPBPD2* were pooled and concentrated to 25 mg ml^{-1} . Aliquots were flash-frozen in liquid nitrogen and stored at 193 K for subsequent use in crystallization.

2.2. Crystallization

Truncated *LmPBPD2* (residues 21–272) with an additional five amino acids (GHMGS) at the N-terminus was crystallized at 295 K using the sitting-drop vapour-diffusion method in 96-well plates (Hampton Research, USA). Initial crystallization trials were carried out by the sparse-matrix method (Jancarik *et al.*, 1991) using commercial kits from Hampton Research (Crystal Screen HT, SaltRX HT, Index HT and PEG/Ion HT) and Emerald Bio (Wizard I, Wizard II, Cryo I and Cryo II). Drops consisting of 0.4 μl protein solution and 0.4 μl reservoir solution were equilibrated against 70 μl reservoir solution. After 7 d, crystals appeared in condition No. 8 of PEG/Ion HT (20% PEG 3350, 0.2 M KCl). The *LmPBPD2* crystals grew to approximate dimensions of $30 \times 15 \times 200 \mu\text{m}$.




Figure 2
Crystals of *LmPBPD2*. The crystals reached approximate dimensions of $30 \times 15 \times 200 \mu\text{m}$ within 7 d.



Figure 3

An X-ray diffraction image from an *LmPBPD2* crystal. The crystal was exposed for 0.5 s over a 1° oscillation range. In the magnified inset, diffraction spots extending to 1.55 Å resolution can be observed.

2.3. X-ray data collection

For X-ray data collection, a single crystal was transferred into reservoir solution supplemented with 20% glycerol and immediately flash-cooled in a nitrogen-gas stream at 100 K. Native X-ray diffraction data were collected using a Pilatus 2M detector on beamline BL-1A at the Photon Factory (PF), Japan. A data set consisting of 180 images of 1° oscillation at a 178 mm crystal-to-detector distance and an exposure time of 0.5 s per image was collected to 1.55 Å resolution. The data were indexed, integrated and scaled using the programs *iMosflm* and *SCALA* from the *CCP4* package (Battye *et al.*, 2011; Evans, 2006). The data-collection statistics are shown in Table 1.

3. Results and discussion

The N-terminal 20 residues of *LmPBPD2*, which contain a putative transmembrane helix, were not included in the expression construct to facilitate its purification and crystallization. *LmPBPD2* was successfully overexpressed in *E. coli* B834(DE3)RIL cells and purified to 98% purity using a nickel-affinity column and anion-exchange chromatography followed by gel-filtration chromatography (Fig. 1). Each litre of *E. coli* culture yielded ~22 mg of *LmPBPD2*. The crystals were obtained using the sitting-drop vapour-diffusion method at 295 K with reservoir solution composed of 0.2 M KCl, 20% (w/v) PEG 3350. The *LmPBPD2* crystals reached dimensions of about 30 × 15 × 200 μm within 7 d (Fig. 2). The crystal diffracted to a resolution of 1.55 Å using synchrotron radiation. The observation of split spots in the diffraction patterns suggests that the mounted crystal might be

twinned (Fig. 3). Fortunately, the diffraction spots from the two crystalline domains did not overlap, and one crystalline domain mainly contributed to the diffraction. Thereby, the data were indexed and integrated as if the crystal were single by excluding one of the non-overlapping reflections. A twinning analysis for the processed data using *phenix.xtriage* estimated the twin fraction to be 0.021, which was a very small value that could be ignored (Adams *et al.*, 2010). Therefore, the data were not detwinned for further processing. The crystal belonged to space group $P2_12_12_1$, with unit-cell parameters $a = 37.7$, $b = 74.7$, $c = 75.1$ Å. The diffraction data set had a resolution range of 37.68–1.55 Å with a completeness of 96.9% and an R_{merge} of 9.1% (Table 1). Assuming the presence of one *LmPBPD2* molecule per asymmetric unit, the Matthews coefficient V_M (Matthews, 1968) was 1.81 Å³ Da⁻¹ with a solvent content of 31.9%, indicating that the crystal had a tightly packed lattice with a low solvent content (Trillo-Muyo *et al.*, 2013). Molecular replacement was carried out using *Phaser* (McCoy, 2007) with the structure of PBP6 from *E. coli* (PDB entry 3it9; Chen *et al.*, 2009), which is the most closely related structure to Lmo2812, sharing 32% amino-acid sequence identity, as a search model. An initial search model yielded a solution with a translation-function Z -score of 10.8 and a rotation-function Z -score of 7.4. Further structural refinement is now in progress.

This research was part of the project titled ‘Marine Extreme Genome Research Center Program’ funded by the Ministry of Oceans and Fisheries, Korea.

References

- Adams, P. D. *et al.* (2010). *Acta Cryst.* **D66**, 213–221.
 Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. W. (2011). *Acta Cryst.* **D67**, 271–281.
 Chen, Y., Zhang, W., Shi, Q., Heseck, D., Lee, M., Mobashery, S. & Shoichet, B. K. (2009). *J. Am. Chem. Soc.* **131**, 14345–14354.
 Evans, P. (2006). *Acta Cryst.* **D62**, 72–82.
 Ghosh, A. S., Chowdhury, C. & Nelson, D. E. (2008). *Trends Microbiol.* **16**, 309–317.
 Hof, H., Nichterlein, T. & Kretschmar, M. (1997). *Clin. Microbiol. Rev.* **10**, 345–357.
 Jancarik, J., Scott, W. G., Milligan, D. L., Koshland, D. E. Jr & Kim, S.-H. (1991). *J. Mol. Biol.* **221**, 31–34.
 Korsak, D., Markiewicz, Z., Gutkind, G. O. & Ayala, J. A. (2010). *BMC Microbiol.* **10**, 239.
 Lovering, A. L., Safadi, S. S. & Strynadka, N. C. (2012). *Annu. Rev. Biochem.* **81**, 451–478.
 Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.
 McCoy, A. J. (2007). *Acta Cryst.* **D63**, 32–41.
 Nelson, D. E. & Young, K. D. (2001). *J. Bacteriol.* **183**, 3055–3064.
 Popham, D. L. & Young, K. D. (2003). *Curr. Opin. Microbiol.* **6**, 594–599.
 Sauvage, E., Kerff, F., Terrak, M., Ayala, J. A. & Charlier, P. (2008). *FEMS Microbiol. Rev.* **32**, 234–258.
 Southwick, F. S. & Purich, D. L. (1996). *N. Engl. J. Med.* **334**, 770–776.
 Trillo-Muyo, S., Jasilionis, A., Domagalski, M. J., Chruszcz, M., Minor, W., Kuisiene, N., Arolas, J. L., Solà, M. & Gomis-Rüth, F. X. (2013). *Acta Cryst.* **D69**, 464–470.
 Vicente, M. F., Pérez-Dáz, J. C., Baquero, F., Angel de Pedro, M. & Berenguer, J. (1990). *Antimicrob. Agents Chemother.* **34**, 539–542.
 Vollmer, W., Blanot, D. & de Pedro, M. A. (2008). *FEMS Microbiol. Rev.* **32**, 149–167.